Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
<p>Abstract</p> <p>Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten <it>ras </it>(KRAS) status has emerged as a predictor of response to epidermal growth factor rece...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-04-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/18 |
| _version_ | 1811314955211767808 |
|---|---|
| author | Li Kuiyuan Ma Ying Kumar Vikas Chang David Z Kopetz Scott |
| author_facet | Li Kuiyuan Ma Ying Kumar Vikas Chang David Z Kopetz Scott |
| author_sort | Li Kuiyuan |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten <it>ras </it>(KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will discuss targeted therapies for colorectal cancers (CRC) based on EGFR signaling pathway and review published data about the potential usefulness of KRAS as a biological marker for response to these therapies. Results from relevant studies published since 2005 and unpublished results presented at national meetings were retrieved and summarized. These studies reflected response (or lack of response) to EGFR-targeted therapies in patients with metastatic CRC as a function of KRAS status. It has become clear that patients with colorectal cancer whose tumor has an activating mutation in KRAS do not respond to monoclonal antibody therapies targeting EGFR. It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies.</p> |
| first_indexed | 2024-04-13T11:21:39Z |
| format | Article |
| id | doaj.art-0497742b26e048d0aeabd115497322bc |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-13T11:21:39Z |
| publishDate | 2009-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-0497742b26e048d0aeabd115497322bc2022-12-22T02:48:48ZengBMCJournal of Hematology & Oncology1756-87222009-04-01211810.1186/1756-8722-2-18Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapyLi KuiyuanMa YingKumar VikasChang David ZKopetz Scott<p>Abstract</p> <p>Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten <it>ras </it>(KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will discuss targeted therapies for colorectal cancers (CRC) based on EGFR signaling pathway and review published data about the potential usefulness of KRAS as a biological marker for response to these therapies. Results from relevant studies published since 2005 and unpublished results presented at national meetings were retrieved and summarized. These studies reflected response (or lack of response) to EGFR-targeted therapies in patients with metastatic CRC as a function of KRAS status. It has become clear that patients with colorectal cancer whose tumor has an activating mutation in KRAS do not respond to monoclonal antibody therapies targeting EGFR. It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies.</p>http://www.jhoonline.org/content/2/1/18 |
| spellingShingle | Li Kuiyuan Ma Ying Kumar Vikas Chang David Z Kopetz Scott Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy Journal of Hematology & Oncology |
| title | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy |
| title_full | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy |
| title_fullStr | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy |
| title_full_unstemmed | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy |
| title_short | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy |
| title_sort | individualized therapies in colorectal cancer kras as a marker for response to egfr targeted therapy |
| url | http://www.jhoonline.org/content/2/1/18 |
| work_keys_str_mv | AT likuiyuan individualizedtherapiesincolorectalcancerkrasasamarkerforresponsetoegfrtargetedtherapy AT maying individualizedtherapiesincolorectalcancerkrasasamarkerforresponsetoegfrtargetedtherapy AT kumarvikas individualizedtherapiesincolorectalcancerkrasasamarkerforresponsetoegfrtargetedtherapy AT changdavidz individualizedtherapiesincolorectalcancerkrasasamarkerforresponsetoegfrtargetedtherapy AT kopetzscott individualizedtherapiesincolorectalcancerkrasasamarkerforresponsetoegfrtargetedtherapy |